Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness
Primary Purpose
Occasional Sleeplessness
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Diphenhydramine Hydrochloride
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Occasional Sleeplessness
Eligibility Criteria
Inclusion Criteria:
- be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month;
- be in good general health without clinically significant disease (no previously diagnosed sleep disorders);
- if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study
Exclusion Criteria:
- have a clinically significant illness within 30 days of Screening;
- are taking medication that could interfere with the study medication;
- have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia;
- are currently taking medications known to effect sleep function;
- have current or past history of serious, severe or unstable physical or psychiatric illness;
- have current diagnosis of severe urinary retention;
- have current diagnosis of untreated narrow angle glaucoma;
- had participated in a clinical drug study or used an investigational new drug during the previous 30 days;
- have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Diphenhydramine Hydrochloride
Placebo
Arm Description
Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
Placebo elixir taken when subjects had trouble falling asleep
Outcomes
Primary Outcome Measures
Mean Latency to Persistent Sleep
Per Protocol population based on subjects who completed treatment crossover
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02578186
Brief Title
Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness
Official Title
Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Procter and Gamble
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present study was conducted to investigate the impact of diphenhydramine hydrochloride on the ability to initiate sleep.
Detailed Description
Diphenhydramine hydrochloride (herein referred to as diphenhydramine) is an antihistamine of the ethanolamine classes with known sleep-inducing properties and is approved by the Food & Drug Administration to reduce the time to sleep onset in individuals having difficulty falling asleep. The goal of the study is to investigate diphenhydramine versus placebo with regard to several sleep parameters, including time to sleep onset, in healthy adult subjects suffering from occasional sleeplessness.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Occasional Sleeplessness
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diphenhydramine Hydrochloride
Arm Type
Experimental
Arm Description
Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo elixir taken when subjects had trouble falling asleep
Intervention Type
Drug
Intervention Name(s)
Diphenhydramine Hydrochloride
Other Intervention Name(s)
Zzzquil
Intervention Description
30 mL at bedtime
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
placebo comparator
Intervention Description
30 mL at bedtime
Primary Outcome Measure Information:
Title
Mean Latency to Persistent Sleep
Description
Per Protocol population based on subjects who completed treatment crossover
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month;
be in good general health without clinically significant disease (no previously diagnosed sleep disorders);
if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study
Exclusion Criteria:
have a clinically significant illness within 30 days of Screening;
are taking medication that could interfere with the study medication;
have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia;
are currently taking medications known to effect sleep function;
have current or past history of serious, severe or unstable physical or psychiatric illness;
have current diagnosis of severe urinary retention;
have current diagnosis of untreated narrow angle glaucoma;
had participated in a clinical drug study or used an investigational new drug during the previous 30 days;
have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness
We'll reach out to this number within 24 hrs